The Lilly MDR-TB Partnership
Local Action, Global Impact
World Bank Donor Forum
Paris, France
20 May 2008
Patrizia Carlevaro
Head, International Aid Unit
Eli Lilly and Company
Facts & Figures

TB kills close to two million people every year

TB kills one person every 20 seconds

4600 people will die of TB by the end of today -- most of whom are in
their most productive working years (ages 15 to 54)

2 billion people are infected with TB worldwide -- 1 in 10 will become sick
with active TB

12 million people worldwide with HIV/AIDS-TB co-infection

One-third of AIDS patients die of TB, making TB the leading cause of
death among AIDS patients

Nearly 500,000 of the 9.2 million new cases of TB every year are
multidrug-resistant

China and India account for half the world’s MDR-TB cases

Highest MDR-TB incidences are in countries of the former Soviet Union
Global MDR-TB Challenge:
Businesses & communities at risk

MDR-TB prolonged and complex
treatment can result in poor patient
compliance and development of drug
resistance

Decline in worker productivity to the
order of US$13 billion annually

Lilly has organized health professionals,
businesses, academic institutions, and
communities in a comprehensive US$135
million MDR-TB program
Since 2003, Lilly has lead a comprehensive approach to
fighting MDR-TB through
Community Support
and Patient
Advocacy
Awareness and
Prevention
Treatment, Training
and Surveillance
Research
Transferring
Technology
Reaching patients
throughout the world
MISSION: to combat the growing MDR-TB
pandemic and to support the Global Plan
to Stop TB.
The Partners
 Aspen Pharmacare, South Africa
 International Council of Nurses
 International Federation of Red Cross &
Red Crescent Societies
 International Hospital Federation
Harvard Medical School & Partners in Health
 Hisun Pharmaceutical, China
 Purdue University, USA
Results Educational Fund
Shasun Chemicals and Drugs, India
 SIA International, Russia
 Stop TB Partnership
 TB Alert and TB Survival Project
 U.S. Centers for Disease Control & Prevention
 World Economic Forum
 World Health Organization
 World Medical Association
Reaching patients
throughout the world
Transfer of Technology

Share Lilly’s specific and general
manufacturing knowledge

Create self-sustaining centers of
manufacturing excellence capable
of providing additional products
and employment


Offer manufacturing firms in MDRTB “hot spots” (China, India,
Russia, South Africa) the
technology to produce two second
line TB drugs

Technical training in manufacturing
and Good Business Practices with
the support from Purdue University

Provide Lilly staff on-site for
technical assistance/training
Support reliable generic producers
to ensure expanded multi-source
availability of the two drugs
Transferring Technology
360 degree approach: examples
Healthcare Professional Education Program
International Council of Nurses (ICN)
Scope/reach: more than 13 million nurses worldwide


Sample 1 activity: Training of Trainers
Sample 2 activity: Development of framework and advocacy for TB
and MDR-TB curriculum in nursing schools
World Medical Association (WMA)
Scope/reach: 7 million physicians worldwide


Sample 1 activity: Develop distance learning course for physicians
addressing the clinical aspects of MDR-TB
Sample 2 activity: Conduct in-country training with local medical
associations
International Hospital Federation (IHF)
Scope/reach: 50,000 hospital facilities worldwide

Sample activity: Development of MDR-TB control manuals and
disseminated to 40,000 public and private hospitals and clinics
360 degree approach: examples
Community Support and Patient Advocacy
International Federation of Red Cross and Red Crescent
(IFRC)

Sample activity: Community support to people living with MDR-TB to
ensure better access to care and improved compliance
Awareness and Prevention
TB Survival Project and TB Alert

Sample activity: Patient-led initiative to raise awareness and engage
patients and their families worldwide
STOP TB Partnership

Sample activity: Advocacy and awareness campaign involving football
star Luis Figo as goodwill ambassador
Research and Development

Establishment of a not-for-profit early phase drug to integrate medicinal
chemistry expertise from the pharmaceutical industry with academic
expertise in chemistry, microbiology and TB (basic biology genetics and
molecular biology)

Includes collaboration with the Infectious Disease Research Institute
(Seattle, USA), National Institute of Allergy and Infectious Diseases
(USA), Global Alliance for TB Drug Development, etc.
360 degree approach: examples
TB and MDR-TB in the workplace
Partnership with the World Economic Forum (WEF)



Develop a Global Awareness Toolkit for Tuberculosis/MDR-TB in the Workplace and
disseminate through WEF member companies
Provide educational material targeting employees and in-plant healthcare staff
Pilot-tested by the WEF in India and being adapted for other high-burden countries
with large business communities
Advocacy and awareness in the workplace
Partnership with the Global Business Coalition (GBC)

GBC scope/reach: 220 cross-cutting multinational companies worldwide (e.g., Coca
Cola Company, Citibank, General Motors, Deutsche Post World Net, L’Oréal,
Siemens, etc.)

Distributed 400,000 card decks with TB awareness/advocacy messages in Beijing train
stations (target: migrant workers)
Contact Information
Dr Patrizia Carlevaro
Head, International Aid Unit
Eli Lilly and Company
Geneva, Switzerland
carlevaro_patrizia@lilly.com
www.lilly.com
www.lillymdr-tb.com